Browsing by Author "Gurbel, Paul A."

Now showing items 1-5 of 5

    • Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium 

      Gorog, Diana A.; Storey, Robert F.; Gurbel, Paul A.; Tantry, Udaya S.; Berger, Jeffrey S.; Chan, Mark Y.; Duerschmied, Daniel; Smyth, Susan S.; Parker, William A.E.; Ajjan, Ramzi A.; Vilahur, Gemma; Badimon, Lina; Berg, Jurrien M.ten; Cate, Hugo ten; Peyvandi, Flora; Wang, Taia T.; Becker, Richard C. (2022-01-13)
      Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients ...

    • The East Asian Paradox : An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease 

      Kim, Hyun Kuk; Tantry, Udaya S.; Smith, Sidney C.; Jeong, Myung Ho; Park, Seung Jung; Kim, Moo Hyun; Lim, Do Sun; Shin, Eun Seok; Park, Duk Woo; Huo, Yong; Chen, Shao Liang; Bo, Zheng; Goto, Shinya; Kimura, Takeshi; Yasuda, Satoshi; Chen, Wen Jone; Chan, Mark; Aradi, Daniel; Geisler, Tobias; Gorog, Diana A.; Sibbing, Dirk; Lip, Gregory Y.H.; Angiolillo, Dominick J.; Gurbel, Paul A.; Jeong, Young Hoon (2020-11-10)
      East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12receptor inhibitors (e.g., ticagrelor and prasugrel) and ...

    • Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial 

      Kubica, Jacek; Adamski, Piotr; Gorog, Diana A.; Kubica, Aldona; Jilma, Bernd; Budaj, Andrzej; Siller-Matula, Jolanta M.; Gurbel, Paul A.; Alexopoulos, Dimitrios; Badarienė, Jolita; Dąbrowski, Paweł; Dudek, Dariusz; Giannitsis, Evangelos; Horszczaruk, Grzegorz; Jaguszewski, Miłosz J.; James, Stefan; Jeong, Young Hoon; Kryjak, Michał; Niezgoda, Piotr; Ostrowska, Małgorzata; Patti, Giuseppe; Romanek, Janusz; Di Somma, Salvatore; Specchia, Giuseppe; Tantry, Udaya; Gąsior, Mariusz; Tycińska, Agnieszka; Wojakowski, Wojciech; Buszko, Katarzyna; Gil, Robert; Gruchała, Marcin; Kasprzak, Jarosław; Kleinrok, Andrzej; Legutko, Jacek; Lesiak, Maciej; Navarese, Eliano P. (2021-09-30)

    • PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection 

      Navarese, Eliano P.; Podhajski, Przemysław; Gurbel, Paul A.; Grzelakowska, Klaudyna; Ruscio, Eleonora; Tantry, Udaya; Magielski, Przemysław; Kubica, Aldona; Niezgoda, Piotr; Adamski, Piotr; Junik, Roman; Przybylski, Grzegorz; Pilaczyńska-Cemel, Marta; Rupji, Manali; Specchia, Giuseppe; Pinkas, Jarosław; Gajda, Robert; Gorog, Diana A.; Andreotti, Felicita; Kubica, Jacek (2023-01-24)
      Background The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein receptor homeostasis, with potential ...

    • Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes 

      Storey, Robert F.; Gurbel, Paul A.; Berg, Jurrien ten; Bernaud, Corine; Dangas, George D.; Frenoux, Jean Marie; Gorog, Diana A.; Hmissi, Abdel; Kunadian, Vijay; James, Stefan K.; Tanguay, Jean Francois; Tran, Henry; Trenk, Dietmar; Ufer, Mike; van der Harst, Pim; Van't Hof, Arnoud W.J.; Angiolillo, Dominick J. (2020-09-01)
      Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). Methods In this double-blind, ...